| domain | established finding | evidence type | key quantitative detail | source/year/DOI or PMID if present | confidence/limitations |
|---|---|---|---|---|---|
| Entity resolution | The requested disease is best resolved as mitochondrial **Leber hereditary optic neuropathy with dystonia** (LHON-dystonia/LHOND), not TIMM8A-related Mohr-Tranebjaerg syndrome. TIMM8A disease is an X-linked nuclear mitochondrial import disorder with hearing-loss–predominant phenotype, whereas LHON-dystonia is a maternal mtDNA disorder centered on optic neuropathy plus movement disorder. (pqac-00000000, pqac-00000002) | Review/database-supported disease distinction | Open Targets links **TIMM8A** to hereditary optic neuropathy only weakly, while classic LHON disease associations center on mtDNA complex I genes; TIMM8A review states pathogenic variants cause Mohr-Tranebjaerg syndrome. | Heinemeyer et al., 2019, DOI: 10.1089/dna.2018.4292; Open Targets context (pqac-00000000) | Moderate confidence for distinction; exact MONDO/OMIM mapping for the rare LHON-dystonia label not directly retrieved here. |
| Primary causal variant | The canonical variant for LHON-dystonia is **MT-ND6 m.14459G>A**. It has long been reported in maternally inherited families with optic neuropathy and dystonia and remains the main genotype linked to this entity. (pqac-00000002, pqac-00000003) | Primary literature summarized in review; clinical cohort context | In a 2020 Chinese rare-mutation LHON series, **4/16** patients carried **m.14459G>A**; **1** had LHON plus dystonia. | Cui et al., 2020, *J Neuro-Ophthalmol*, DOI: 10.1097/WNO.0000000000000799 | High confidence that m.14459G>A is disease-defining; low sample size for phenotype frequencies. |
| Additional genetic heterogeneity | LHON-plus phenotypes with dystonia can also occur with other mtDNA complex I variants or double mutations, but these are not the classic LHON-dystonia entity. (pqac-00000001, pqac-00000002) | Case report + review | A 2020 case had double **MT-ND4/MT-ND6** mutations with optic neuropathy, dystonia, and transverse myelitis; not a pure m.14459G>A-only presentation. | Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z | Moderate confidence; demonstrates phenotypic overlap, not primary disease definition. |
| Inheritance | LHON-dystonia follows **maternal (mitochondrial) inheritance** because the causal variants are in mtDNA. (pqac-00000001, pqac-00000002) | Review + case report | General LHON shows maternal transmission and incomplete penetrance; most primary LHON mutations are often homoplasmic. | Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270; Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z | High confidence for inheritance; penetrance estimates specific to m.14459G>A were not retrieved. |
| Heteroplasmy/homoplasmy | Published LHON literature indicates many primary LHON mutations are **homoplasmic**, and review evidence specifically notes homoplasmic inheritance has been described with **m.14459G>A** despite variable clinical expression. (pqac-00000001, pqac-00000002) | Review/case-based synthesis | No robust disease-specific heteroplasmy percentage retrieved for LHON-dystonia. | Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 | Moderate confidence; variant-level quantitative heteroplasmy data are sparse in the retrieved evidence. |
| Mechanism: biochemical lesion | MT-ND6 m.14459G>A causes a **respiratory chain complex I defect**. Cybrid experiments were used to assign the defect directly to the mtDNA variant. (pqac-00000002) | Functional primary study summarized in review | The key mechanistic assignment was made in transmitochondrial cybrids. | Jun et al., 1996, *Mol Cell Biol*, DOI: 10.1128/MCB.16.3.771 | High confidence for mechanism; original article text was not directly extracted here, but the review cites it specifically. |
| Mechanism: cell injury cascade | General LHON pathophysiology supports that complex I dysfunction drives reduced oxidative phosphorylation, oxidative stress, impaired glutamate handling, and increased apoptotic susceptibility in retinal ganglion cells; these mechanisms are used to explain LHON-dystonia as a complex I neurodegenerative phenotype. (pqac-00000002) | Review of cellular/model studies | No LHON-dystonia-specific omics dataset retrieved; mechanism largely extrapolated from LHON/cybrid work. | Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 | Moderate confidence; strong biological plausibility but limited subtype-specific mechanistic profiling. |
| Core phenotype | The syndrome combines **Leber hereditary optic neuropathy** with **dystonia**; dystonia may precede ocular manifestations by years in mtDNA movement-disorder literature summarized by reviews. (pqac-00000002) | Review of case reports/families | No pooled frequency estimate for dystonia among m.14459G>A carriers retrieved. | Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 | Moderate confidence; based mainly on rare families/case reports. |
| MRI / neuroimaging | In rare-mutation LHON, MRI can show **optic atrophy** and optic pathway signal changes; in the patient with **m.14459G>A plus dystonia**, MRI also showed **basal ganglia T2 signal abnormalities**. (pqac-00000003) | Clinical cohort | In the 16-patient series: optic atrophy in **62.5% (10/16)**; increased optic-nerve T2 signal in **38% (6/16)**; the single LHON+dystonia patient had basal-ganglia signal change. | Cui et al., 2020, DOI: 10.1097/WNO.0000000000000799 | Moderate confidence; useful radiologic clue, but data come from a small rare-mutation cohort. |
| Visual severity / course | Rare-mutation LHON generally causes substantial visual disability; in the same cohort most eyes were severely impaired. (pqac-00000003) | Clinical cohort | **75% (24/32 eyes)** had worst Snellen BCVA **≤0.1**; mean onset age in the cohort was **15 ± 6 years**; male:female **15:1**. | Cui et al., 2020, DOI: 10.1097/WNO.0000000000000799 | Moderate confidence for rare-mutation LHON context; not specific to all LHON-dystonia cases. |
| Environmental / modifier factors | General LHON penetrance is modified by **sex**, mtDNA background/haplogroup, and reported environmental triggers such as **tobacco and alcohol**; estrogen has been discussed as potentially protective. (pqac-00000001) | Review/case-report background | No LHON-dystonia-specific exposure study retrieved. | Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z | Moderate confidence for LHON overall; low confidence for direct subtype-specific effect sizes. |
| 2023 diagnostic cohort context | A large 2023 hereditary optic neuropathy diagnostic series provides context for how unusual LHON-dystonia is relative to standard LHON. Among index cases diagnosed with LHON, the vast majority carried the 3 common LHON variants rather than rare variants like m.14459G>A. | Large retrospective diagnostic cohort | Positive LHON diagnosis in **199/1,126 (18%)** index cases; among these, **92% (184/199)** had one of 3 major mtDNA variants: **m.11778G>A 66.5%**, **m.3460G>A 15%**, **m.14484T>C 11%**. | Rocatcher et al., 2023, *Brain*, DOI: 10.1093/brain/awac395 | High confidence for diagnostic context; does not specifically enumerate LHON-dystonia. |
| Diagnostic approach | Diagnosis should integrate neuro-ophthalmic phenotype with **mtDNA testing**, especially for primary LHON variants and rarer complex I variants in atypical/LHON-plus cases; MRI abnormalities do not exclude LHON. (pqac-00000003) | Clinical cohort + general disease context | MRI optic pathway signal abnormality occurred in **38%** of the rare-mutation cohort, underscoring that inflammatory-appearing imaging can still occur in LHON. | Cui et al., 2020, DOI: 10.1097/WNO.0000000000000799 | Moderate confidence; no formal subtype-specific guideline retrieved. |
| Current management | There is **no established disease-specific therapy for LHON-dystonia**. Management is extrapolated from LHON and movement-disorder care: visual rehabilitation, mitochondrial counseling, and symptomatic dystonia treatment. (pqac-00000001, pqac-00000002) | Review/case-based practice inference | No controlled trial specific to m.14459G>A LHON-dystonia retrieved. | Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z; Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 | Moderate confidence; evidence gap for subtype-directed treatment. |
| Trials / real-world implementation | Recent interventional development is concentrated in **general LHON**, especially **ND4 gene therapy** rather than m.14459G>A LHON-dystonia. Active/completed trials include **NCT07406854**, **NCT05293626**, **NCT03406104**, **NCT03293524**, **NCT03153293**, **NCT02064569**, **NCT01267422**, and nicotinamide/metabolomics studies. (pqac-00000000) | Clinical trial registry | Example enrollments: **95** (NCT07406854), **98** (NCT03293524), **159** (NCT03153293), **19** (NCT02064569). | ClinicalTrials.gov records via tool context (pqac-00000000) | High confidence that therapeutic development is active in LHON broadly; none retrieved were specific to MT-ND6 m.14459G>A dystonia. |
| Evidence gaps | Major gaps remain in **epidemiology**, **penetrance**, **natural history**, **modifier genes**, **formal diagnostic criteria**, **biomarkers**, **prognosis**, and **animal/subtype-specific models** for LHON-dystonia. Most evidence derives from isolated families, case reports, or broader LHON reviews. (pqac-00000001, pqac-00000002, pqac-00000003) | Evidence synthesis | No robust prevalence/incidence estimate or prospective natural-history cohort specific to LHON-dystonia was retrieved. | Based on retrieved literature set (pqac-00000001, pqac-00000002, pqac-00000003) | High confidence that evidence is sparse due to extreme rarity. |


*Table: This compact table summarizes the strongest retrieved evidence for Leber hereditary optic neuropathy with dystonia, emphasizing its distinction from TIMM8A disease, the central role of MT-ND6 m.14459G>A, and what is known versus still missing from the literature.*